CAMK2 Therapeutics Network

CAMK2 — an abbreviation for calcium/calmodulin dependent protein kinase 2 — is a family of four similar proteins that are abundant in the brain and important for normal electrical signaling. Neurodevelopmental disorders associated with mutations in these proteins were first described in 2017 by Kury and van Woerden et al. Their scientific breakthrough gave a name to the developmental delay, seizures and behavioral abnormalities we had been seeing in our children.